---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-213726"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2024-09-05T23:59:59+00:00"
generated_at: "2026-05-31T06:14:13.660751+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Lantheus appoints Julie Eastland to Board of Directors, effective Sept 3, 2024

## Summary
- Board size increased to ten directors; Eastland is a Class I director and Audit Committee member.
- Eastland qualifies as independent under Nasdaq rules; compensation includes $60K/yr cash plus prorated equity grant valued at $266,666.67.
- She brings biotech and finance experience, most recently CEO of Harpoon Therapeutics until its acquisition by Merck in March 2024.
- No arrangements or family relationships with existing directors or officers; no disclosable transactions.

## SEC filing metadata
- accession: 0001193125-24-213726
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2024-09-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000119312524213726/0001193125-24-213726-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000119312524213726/d886086d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-213726
- JSON: https://secwatch.observer/filing/0001193125-24-213726.json
- Plain text: https://secwatch.observer/filing/0001193125-24-213726.txt

## Key facts
- Executive change
  Julie Eastland was appointed as Director at Lantheus Holdings, Inc..
  - Action: appointed
  - Role: Director
  source text: On September 3, 2024, the board of directors of Lantheus Holdings, Inc. (the “Board”), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Julie Eastland, an experienced biotechnology and financial executive, to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1521036/000119312524213726/0001193125-24-213726-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.